| XLS |
|
|
|
| ||
|
€ million |
Q1 – 2013 |
Q1 – 2012 | ||
| ||||
|
Profit after tax |
269.0 |
175.11 | ||
|
Items of other comprehensive income that will not be reclassified to the income statement in subsequent periods: |
|
| ||
|
Remeasurement of the net defined benefit liability |
|
| ||
|
Changes in remeasurement |
–87.8 |
–1 | ||
|
Deferred taxes |
14.7 |
– | ||
|
Changes recognized in equity |
–73.1 |
–1 | ||
|
|
–73.1 |
– | ||
|
Items of other comprehensive income that may be reclassified to the income statement in subsequent periods: |
|
| ||
|
Available-for-sale financial assets |
|
| ||
|
Fair value adjustments |
0.7 |
– | ||
|
Reclassification to income statement |
– |
– | ||
|
Deferred taxes |
–0.4 |
– | ||
|
Changes recognized in equity |
0.3 |
– | ||
|
Derivative financial instruments |
|
| ||
|
Fair value adjustments |
–21.4 |
25.6 | ||
|
Reclassification to income statement |
–3.1 |
42.0 | ||
|
Deferred taxes |
7.5 |
–10.1 | ||
|
Changes recognized in equity |
–17.0 |
57.5 | ||
|
Exchange differences on translating foreign operations |
|
| ||
|
Changes taken directly to equity |
21.0 |
–19.4 | ||
|
Reclassification to income statement |
– |
– | ||
|
Changes recognized in equity |
21.0 |
–19.4 | ||
|
|
4.3 |
38.1 | ||
|
Other comprehensive income |
–68.8 |
38.11 | ||
|
Comprehensive income |
200.2 |
213.21 | ||
|
of which attributable to Merck KGaA shareholders |
195.4 |
210.91 | ||
|
of which attributable to non-controlling interest |
4.8 |
2.3 | ||